ChartMill assigns a Buy % Consensus number of 85% to RAPP. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-08 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-19 | BTIG | Initiate | Buy |
| 2025-11-07 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-09-16 | Truist Securities | Initiate | Buy |
| 2025-09-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-08 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-08 | JMP Securities | Initiate | Market Outperform |
| 2024-10-18 | Jones Trading | Initiate | Buy |
| 2024-07-02 | TD Cowen | Initiate | Buy |
| 2024-07-02 | Stifel | Initiate | Buy |
| 2024-07-02 | Jefferies | Initiate | Buy |
15 analysts have analysed RAPP and the average price target is 53.3 USD. This implies a price increase of 75.66% is expected in the next year compared to the current price of 30.34.
The consensus rating for RAPPORT THERAPEUTICS INC (RAPP) is 85.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.